Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

(2017) Janet Lau et al.   Nature Communications

A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice

(2017) Fei Tang et al.   eLife

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

(2017) Jan Willem Kleinovink et al.   OncoImmunology

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE